Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Masitinib plus gemcitabine versus placebo plus gemcitabine, with second-line masitinib plus FOLFIRI.3 versus placebo plus FOLFIRI.3, in advanced pancreatic cancer
2013-002293-41Phase 3Completed
- Sponsor
- AB Science
- Start
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of masitinib in pancreatic cancer (PC) (4 arms), sponsored by AB Science. Primary endpoint: Overall survival. Started Jan 2014; status: completed.
02
Drugs
masitinib
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on 2013-002293-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002293-41.